DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Zhu AX, Kang Y-K, Yen C-J. , et al; REACH-2 Study Investigators.
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol 2019;
20 (02) 282-296
We do not assume any responsibility for the contents of the web pages of other providers.